Opportunity Information: Apply for RFA DK 16 001

  • The HHS-NIH11 in the food and nutrition, health sector is offering a public funding opportunity titled "Improving Diabetes Management in Pre-teens, Adolescents and/or Young Adults with Type 1 Diabetes (DP3)" and is now available to receive applicants.
  • Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847,.
  • This funding opportunity was created on Dec 08, 2015 and posted on Dec 08, 2015.
  • Applicants must submit their applications by Jun 22, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
  • Each selected applicant is eligible to receive up to $1,400,000.00 in funding.
  • The number of recipients for this funding is limited to 3 candidate(s).
  • Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
Apply for RFA DK 16 001

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:

Opportunity Summary:

The grant opportunity titled "Improving Diabetes Management in Pre-teens, Adolescents and/or Young Adults with Type 1 Diabetes (DP3)" (Funding Opportunity Number RFA-DK-16-001) is a discretionary NIH grant from HHS (listed under HHS-NIH11) focused on developing better ways to help young people with type 1 diabetes manage their condition. The central purpose is not to fund a large, definitive clinical trial right away, but to support the creation and early testing of new, practical interventions that could later be evaluated in a full-scale efficacy study. It targets a challenging period for diabetes care, when developmental changes, school or work transitions, and shifting responsibility for self-care often make consistent management harder.

The FOA specifically invites institutions and organizations to design, refine, and pilot test innovative strategies aimed at improving diabetes management in three age bands: pre-teens ages 10 to 12, adolescents ages 13 to 18, and young adults ages 19 to 30. Applicants can focus on one group or potentially address more than one, as long as the intervention is clearly tailored to the needs and realities of the chosen population. The emphasis on these age ranges reflects well-known gaps in diabetes outcomes during adolescence and young adulthood, when adherence, engagement with care, and glycemic control often worsen and the risk of acute and longer-term complications can increase.

A key expectation is that by the end of the funding period, the project will produce an intervention that is "well-developed and well-characterized." In practical terms, that means the strategy should move beyond a simple concept and become something structured enough to replicate: clear intervention components, defined delivery methods, documented training requirements for staff (if relevant), and an implementation approach that can realistically be used in the intended settings. The FOA highlights several specific benchmarks for success: the intervention should be demonstrated to be safe, feasible to implement, and acceptable to the target population. Safety here includes not only medical safety (for example, avoiding increased risk of hypoglycemia) but also broader concerns such as burden, unintended effects on mental health, or negative impacts on family dynamics. Feasibility means the intervention can be delivered without unrealistic resources, time commitments, or specialized infrastructure that would make it impossible to scale. Acceptability means the intended users (youth/young adults and often families or caregivers) find it usable and worthwhile, which is especially important for interventions that rely on sustained engagement.

The program is structured so that, if early results are promising, the intervention should be ready to move into a larger efficacy trial after the grant ends. That readiness typically implies that the pilot work has generated enough preliminary data to justify a bigger study, clarified recruitment and retention strategies for the population, established workable outcome measures, and resolved major uncertainties in how the intervention should be delivered. In other words, NIH is paying for the risky but necessary early-stage work that often determines whether a novel idea can survive contact with real-world clinical care and day-to-day life.

From a funding and administrative standpoint, this opportunity uses the NIH grant funding instrument and falls under the Health and Food and Nutrition activity categories. It is associated with CFDA numbers 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research) and 93.847 is commonly tied to NIDDK-supported research. The award ceiling listed is $1,400,000, and the agency anticipated making about three awards. The FOA was posted on December 8, 2015, with a closing date of June 22, 2016 (both original and current closing dates match), which indicates it was a time-limited solicitation rather than an open-ended program announcement.

Eligibility is broad and includes many types of applicants, reflecting an interest in pulling innovation from multiple sectors. Eligible applicants include state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations (including both 501(c)(3) and non-501(c)(3) entities) that are not institutions of higher education; for-profit organizations (other than small businesses); and small businesses. This range signals that NIH was open to interventions developed in clinical settings, community or school environments, academic research centers, digital health companies, or partnerships that combine these strengths.

Overall, the opportunity is best understood as support for the "build and prove it can work in the real world" phase of intervention development for type 1 diabetes management in youth and young adults. The deliverable NIH is trying to buy with this FOA is a credible, pilot-tested intervention package, backed by evidence that people will use it, settings can implement it, and it does not create new risks. If those boxes are checked and early signals suggest benefit, the project should be positioned to compete for subsequent funding to test efficacy at a larger scale.

Frequently Asked Questions (FAQs)

What is the title and funding opportunity number for this grant?

The opportunity is titled "Improving Diabetes Management in Pre-teens, Adolescents and/or Young Adults with Type 1 Diabetes (DP3)" and the Funding Opportunity Number is RFA-DK-16-001.

Which federal agency is offering this grant?

This is a discretionary NIH grant from the U.S. Department of Health and Human Services (HHS), listed under HHS-NIH11.

What is the main purpose of this funding opportunity?

The central purpose is to support the creation, refinement, and early testing (pilot testing) of new, practical interventions that help young people with type 1 diabetes manage their condition. It is focused on developing and de-risking interventions so they are ready for a later, full-scale efficacy trial.

Is this grant meant to fund a large definitive clinical trial?

No. The opportunity is explicitly positioned as early-stage intervention development and pilot testing, not as funding for a large, definitive clinical trial right away.

Who is the target population for the interventions developed under this FOA?

The FOA targets young people with type 1 diabetes across three age bands: pre-teens (ages 10 to 12), adolescents (ages 13 to 18), and young adults (ages 19 to 30).

Can an applicant focus on only one age group, or must they address all three?

Applicants can focus on one age band or address more than one, as long as the intervention is clearly tailored to the needs and realities of the chosen population.

Why does the FOA emphasize pre-teens, adolescents, and young adults?

These age ranges are highlighted because diabetes outcomes often worsen during adolescence and young adulthood due to developmental changes, transitions in school or work, and shifting responsibility for self-care. During these periods, adherence and engagement with care can decline, glycemic control often deteriorates, and the risk of complications can increase.

What types of projects are encouraged under this opportunity?

The FOA invites institutions and organizations to design, refine, and pilot test innovative strategies aimed at improving diabetes management in the specified age ranges. The emphasis is on practical, real-world interventions that can be replicated and implemented in intended settings.

What does NIH expect projects to deliver by the end of the funding period?

NIH expects a "well-developed and well-characterized" intervention. In practical terms, that means a structured, replicable intervention package with clear components, defined delivery methods, documented training requirements for staff (if relevant), and a realistic implementation approach suitable for intended settings.

What are the key benchmarks for success mentioned in the FOA?

The FOA highlights several benchmarks: the intervention should be demonstrated to be safe, feasible to implement, and acceptable to the target population.

What does "safety" mean in the context of this FOA?

Safety includes medical safety (for example, avoiding increased risk of hypoglycemia) and broader considerations such as participant burden, unintended effects on mental health, and possible negative impacts on family dynamics.

What does "feasibility" mean for these projects?

Feasibility means the intervention can be delivered without unrealistic resources, time commitments, or specialized infrastructure that would make it impossible to scale or implement in real-world settings.

What does "acceptability" mean and why is it important here?

Acceptability means the intended users (youth/young adults and often families or caregivers) find the intervention usable and worthwhile. This matters because many diabetes-management strategies depend on sustained engagement over time.

What is meant by "pilot testing" in this funding opportunity?

Pilot testing here refers to early testing intended to show that an intervention can be delivered as planned, is safe, feasible, and acceptable, and can produce enough preliminary evidence to justify moving to a larger efficacy study later.

What should a successful project be ready to do after the grant ends?

If early results are promising, the intervention should be positioned to move into a larger efficacy trial. This typically implies the pilot work produced enough preliminary data to support a bigger study, clarified recruitment and retention strategies, established workable outcome measures, and resolved major uncertainties about delivery.

What activity categories does this opportunity fall under?

The opportunity is listed under the Health and Food and Nutrition activity categories.

What CFDA number(s) are associated with this FOA?

The FOA is associated with CFDA number 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research), which is commonly tied to NIDDK-supported research.

What is the maximum award amount (award ceiling)?

The listed award ceiling is $1,400,000.

How many awards did the agency anticipate making?

The agency anticipated making about three awards.

When was this funding opportunity posted, and what was the application deadline?

The FOA was posted on December 8, 2015. The closing date was June 22, 2016, and the original and current closing dates match, indicating it was a time-limited solicitation.

What types of organizations are eligible to apply?

Eligibility is broad. Eligible applicants include: state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations (both 501(c)(3) and non-501(c)(3) entities) that are not institutions of higher education; for-profit organizations (other than small businesses); and small businesses.

Does the eligibility list suggest the FOA is open to non-academic or private-sector applicants?

Yes. The inclusion of nonprofits, for-profit organizations, and small businesses suggests NIH was open to interventions developed in a variety of environments, including clinical settings, schools and community settings, academic research centers, digital health companies, or partnerships that combine these strengths.

What is the overall "phase" of work NIH is trying to support with this FOA?

This FOA is best understood as support for the "build and prove it can work in the real world" phase of intervention development: developing a credible intervention package and generating early evidence that people will use it, settings can implement it, and it does not introduce new risks.

Browse more business programs for Diabetes Research

Browse more opportunities from the same agency: HHS-NIH11

Browse more opportunities from the same category: Food and Nutrition, Health

Next opportunity: Examination of Survivorship Care Planning Efficacy and Impact (R01)

Previous opportunity: Request for Information (RFI) DE-FOA-0001460: Co-Optimization of Fuels and Engines

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA DK 16 001

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA DK 16 001) also looked into and applied for these:

Funding Opportunity
Developmental Centers for Interdisciplinary Research in Benign Urology (P20) Apply for RFA DK 16 012

Funding Number: RFA DK 16 012
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: $200,000
Advancing Erythroid Cell Biology (R01) Apply for PA 16 039

Funding Number: PA 16 039
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: Case Dependent
SBIR/STTR Commercialization Readiness Pilot (CRP) Program: Technical Assistance and Late Stage Development (SB1) Apply for PAR 16 027

Funding Number: PAR 16 027
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: Case Dependent
Understanding Barriers and Facilitators to Type 1 Diabetes Management in Adults (DP3) Apply for RFA DK 16 002

Funding Number: RFA DK 16 002
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: $2,500,000
Elucidating HIV and HIV-treatment Associated Metabolic/Endocrine Dysfunction (R01) Apply for RFA DK 16 014

Funding Number: RFA DK 16 014
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: $500,000
Innovative Research in HIV in Kidney, Urology, and Hematology (R01) Apply for RFA DK 16 015

Funding Number: RFA DK 16 015
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: $500,000
George M. O'Brien Urology Cooperative Research Centers Program (U54) Apply for RFA DK 16 013

Funding Number: RFA DK 16 013
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: $1,000,000
Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44) Apply for RFA DK 16 004

Funding Number: RFA DK 16 004
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: Case Dependent
Psychosocial and Behavioral Mechanisms in Bariatric Surgery (R01) Apply for RFA DK 16 017

Funding Number: RFA DK 16 017
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: $500,000
Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21) Apply for PAR 16 064

Funding Number: PAR 16 064
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: $125,000
Limited Competition for the Continuation of the Scientific Data Research Center (SDRC) for the NIDDK Gastroparesis Consortium (U24) Apply for RFA DK 16 507

Funding Number: RFA DK 16 507
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: $1,000,000
Clinical Centers to Investigate the Pathogenesis, Etiology, and Treatment of Gastroparesis through the NIDDK Gastroparesis Consortium (U01) Apply for RFA DK 16 010

Funding Number: RFA DK 16 010
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: $250,000
Silvio O. Conte Digestive Diseases Research Core Centers (P30) Apply for RFA DK 16 019

Funding Number: RFA DK 16 019
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: $750,000
NIDDK Program Projects (P01) Apply for PAR 16 127

Funding Number: PAR 16 127
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: $6,250,000
High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2) Apply for PAR 16 126

Funding Number: PAR 16 126
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: Case Dependent
Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01) Apply for PAR 16 121

Funding Number: PAR 16 121
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: Case Dependent
Limited Competition: Small Grant Program for NIDDK K01/K08/K23 Recipients (R03) Apply for PAR 16 148

Funding Number: PAR 16 148
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: $50,000
Advances in Polycystic Kidney Disease (R01) Apply for PA 16 159

Funding Number: PA 16 159
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: Case Dependent
Human Islet Distribution Coordinating Center (UC4) Apply for RFA DK 16 023

Funding Number: RFA DK 16 023
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: $1,300,000
Limited Competition: Rare Diseases Clinical Research Network (RDCRN) Project Supplements for Clinical Trials to Repurpose Drugs in Collaboration with E-Rare Awardees (Admin Supp) Apply for PA 16 183

Funding Number: PA 16 183
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: Case Dependent

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

USGrants.org applicant portal membership

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 16 001", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.